| Vol. 4.23 – 26 June, 2020 |
| |
|
|
| Scientists identified a negative feedback loop comprising hepatic endoplasmic reticulum (ER) stress and micro RNA (miRNA)‐26a in nonalcoholic fatty liver disease pathogenesis. Combining miRNA dot blot array and quantitative PCR, they found that miR‐26a was specifically induced by ER stress in liver cells. [Hepatology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Mechanism dissection revealed that miR-92a-2-5p from the exosomes could target the 3′UTR of androgen receptor (AR) mRNA to suppress AR translation, altering the PHLPP/p-AKT/β-catenin signaling to increase liver cancer cells invasion. [Cell Death & Differentiation] |
|
|
|
| The roles of calcium silicate (CS)-activated H9 cells in liver injury repair were tested by cell tracking and immunohistochemical staining. Results indicated that high concentrations of CS extracts initially enhanced definitive endodermal (DE) lineage, followed by gradual DE differentiation at low CS concentrations. [Applied Materials Today] |
|
|
|
| Treatment with either of two bone morphogenetic protein (BMP) inhibitors reduced hepatic triglyceride content in diabetic mice. BMP inhibitor-induced decrease in hepatic triglyceride levels were associated with decreased mRNA encoding Dgat2, an enzyme integral to triglyceride synthesis. [Scientific Reports] |
|
|
|
| Mutation of the hepatocyte nuclear factor (HNF)-1 binding site significantly decreased the promoter activity in hepatocytes, and the promoter carrying the mutated HNF-1 site was not transactivated by co-transfection of HNF-1 in a non-hepatic cell line. [Scientific Reports] |
|
|
|
| Using in vitro and in vivo approaches, the authors evaluated apoptosis and lipid metabolism. IFN-α-2b induced changes in hepatic cholesterol mass due to decreased synthesis and increased secretion. [Cytokine] |
|
|
|
| Researchers explored the relationship between the relevant regulatory factors and the epithelial-mesenchymal transition signaling pathways in the various intrahepatic cells. [Biomedicine & PharmacoTherapy] |
|
|
|
| Scientists found that luteolin (20 μM) + lycopene (10 μM) was the best therapeutic combination in sodium palmitate (PA)-induced HepG2 cells, and significantly improved cell viability and lipid accumulation in PA-induced HepG2 cells and primary hepatocytes. [Life Sciences] |
|
|
|
| Researchers found fibroblast growth factor receptor 4 (FGFR4) was overexpressed in hepatocellular carcinoma cell lines HepG2 and Hep3B. They used PD173074, an FGFR4 inhibitor, to explore the role of FGFR4 and its underlying mechanism in these cell lines. [PLoS One] |
|
|
|
|
| Scientists give an overview of T cell receptors identified from viral hepatitis research and discuss how translational lessons learned from cancer immunotherapy can be applied to the field. [Cells] |
|
|
|
| The authors focus on the current studies of the MDM2–p53 axis in hepatocellular carcinoma, and specifically discuss the impact of MDM2–p53 axis dysfunction by viral infection and metabolic disease in the transformation of normal hepatocytes into hepatoma cells. [Cell Death Discovery] |
|
|
|
|
| Assembly Biosciences, Inc. have announced the initiation of a Phase II trial of their potent, second-generation core inhibitor, ABI-H2158, for patients with HBeAg positive chronic hepatitis B infection without cirrhosis. [Assembly Biosciences, Inc.] |
|
|
|
| Celsion Corporation have affirmed that the independent data monitoring mommittee is scheduled to meet during the first half of July to conduct the second pre-planned interim safety and efficacy analysis of the Phase III OPTIMA Study with ThermoDox® plus radiofrequency ablation in patients with hepatocellular carcinoma, or primary liver cancer. [Celsion Corp.] |
|
|
|
| On 24 June, the US National Institutes of Health (NIH) described the actions it will take when alerted to reports of unsafe behaviour, including restricting scientists from peer-review panels, holding back pending grants and refusing university requests to transfer funding to other institutions in cases where a harasser changes jobs. [Nature News] |
|
|
|
|
| July 20 – July 22 Virtual |
|
|
|
|
|
| Deep Genomics – Toronto, Ontario, Canada |
|
|
|
| University of Gothenburg – Gothenburg, Sweden |
|
|
|
| Columbia University Medical Center – New York, New York, United States |
|
|
|
| Beam Therapeutics – Cambridge, Massachusetts, United States |
|
|
|
| Yale University – New Haven, Connecticut, United States |
|
|
|
|